CGTLive’s Weekly Rewind – August 12, 2022

Article

Review top news and interview highlights from the week ending August 12, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Zolgensma Gene Therapy Linked to 2 Deaths in SMA Patients, Novartis Reports

The 2 deaths, due to acute liver failure, occurred in patients treated in Kazakhstan and Russia.

2. Ide-Cel Shows Benefit in Earlier Use in R/R Multiple Myeloma

A recent comparison of health-related quality of life scores also favored ide-cel over belantamab mafodotin treatment.

3. UniQure Pauses High Dose of AMT-130 Huntington Disease Gene Therapy for Severe Adverse Events

No such adverse events have occurred in the lower-dose group.

4. First Patient Dosed in Sickle Cell Gene Therapy Clinical Trial From Graphite Bio

Nula-cel is intended to directly correct the mutation that causes sickle cell disease.

5. Frontotemporal Dementia Gene Therapy Trial Initiates Dosing

PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.